CJ Bioscience Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	2,819	8,309	64,095	49,324	62,060	13,255
Short-Term Investments	53,000	67,000	-	-	18,020	-
Trading Asset Securities	-	-	-	-	-	26,020
Cash & Short-Term Investments	55,819	75,309	64,095	49,324	80,080	39,275
Cash Growth	32.19%	17.50%	29.95%	-38.41%	103.89%	26.35%
Accounts Receivable	244.9	72.57	160.91	303.82	233.62	99.46
Other Receivables	629.45	623.2	178.66	523.06	474.16	257.47
Receivables	874.35	695.77	339.57	826.88	707.78	356.93
Inventory	166.6	128.75	157.82	76.16	145.83	364.31
Prepaid Expenses	376.24	294.56	355.71	446.57	259.18	499.9
Other Current Assets	264.42	333.6	262.22	258.72	362.03	592.63
Total Current Assets	57,500	76,762	65,210	50,932	81,555	41,089
Property, Plant & Equipment	5,522	8,907	12,707	14,364	9,856	19,991
Long-Term Investments	2	2	2	2	0	-
Other Intangible Assets	11,785	12,499	12,397	1,016	114.13	103.95
Other Long-Term Assets	1,526	1,439	811.16	25,075	24,830	12,178
Total Assets	76,336	99,610	91,128	91,389	116,355	73,362
Accounts Payable	184.17	220.83	122.82	336.65	287.75	708.93
Accrued Expenses	2,698	3,234	3,966	3,996	140.94	169.76
Short-Term Debt	6,527	6,365	3,971	23,588	18,441	-
Current Portion of Leases	1,279	1,824	1,869	1,547	1,361	205.9
Other Current Liabilities	4,080	6,882	4,793	5,511	3,606	1,919
Total Current Liabilities	14,769	18,525	14,722	34,979	23,836	3,004
Long-Term Debt	-	-	-	-	-	35,081
Long-Term Leases	420.85	1,162	2,692	3,831	4,088	479.37
Pension & Post-Retirement Benefits	130.98	-	65.47	-	-	-
Other Long-Term Liabilities	1,854	2,166	2,152	2,924	577.4	314.4
Total Liabilities	17,175	21,853	19,633	41,734	28,502	38,878
Common Stock	6,533	6,533	4,556	2,939	2,937	1,946
Additional Paid-In Capital	189,419	189,419	151,426	108,066	112,186	40,993
Retained Earnings	-137,936	-119,067	-85,951	-62,738	-28,035	-8,763
Comprehensive Income & Other	1,145	872.04	1,465	1,389	765.25	307.61
Shareholders' Equity	59,161	77,757	71,496	49,655	87,853	34,484
Total Liabilities & Equity	76,336	99,610	91,128	91,389	116,355	73,362
Total Debt	8,227	9,351	8,533	28,966	23,891	35,766
Net Cash (Debt)	47,591	65,958	55,562	20,357	56,190	3,509
Net Cash Growth	41.17%	18.71%	172.93%	-63.77%	1501.15%	-88.44%
Net Cash Per Share	3888.58	7111.76	7843.75	3463.50	13214.21	908.96
Filing Date Shares Outstanding	13.07	13.07	9.11	5.88	5.87	3.89
Total Common Shares Outstanding	13.07	13.07	9.11	5.88	5.87	3.89
Working Capital	42,732	58,236	50,488	15,953	57,718	38,085
Book Value Per Share	4528.04	5951.30	7845.89	8446.71	14957.10	8859.45
Tangible Book Value	47,376	65,257	59,098	48,640	87,739	34,380
Tangible Book Value Per Share	3626.03	4994.63	6485.40	8273.89	14937.67	8832.74
Land	-	-	-	-	-	13,973
Buildings	-	-	-	-	-	2,563
Machinery	-	14,051	13,686	10,339	4,411	3,488
Construction In Progress	-	-	-	521.7	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.